Overview

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

Status:
Completed

Trial end date:
2021-01-18

Target enrollment:

Participant gender:

Summary

This was a multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with Lutathera plus best supportive care (30 mg Octreotide LAR) to treatment with high dose (60 mg) Octreotide LAR in participants with metastasized or locally advanced, inoperable, somatostatin receptor positive, histologically proven midgut carcinoid tumours with progression despite LAR treatment.

Phase:

Phase 3

Details

Lead Sponsor:

Advanced Accelerator Applications

Collaborator:

Pierrel Research Europe GmbH

Treatments:

Lutetium Lu 177 dotatate
Octreotide
Somatostatin